Post-market re-assessment for Zhui-Feng Tou-Gu capsule in the treatment of lumbar disc herniation

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ITMCTR

Registry ID

ITMCTR2000002894

Enrollment

Unknown

Registered

2020-01-04

Start date

2020-01-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar disc herniation

Interventions

Experimental group:Zhuifengtougu Capsules

Control group:Do not take Zhuifengtougu Capsules and its similar Chinese herbal pieces and proprietary Chinese Medicine

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Aged 18-75 years; (2) those meeting the diagnostic criteria for lumbar disc herniation.

Exclusion criteria

Exclusion criteria: (1) Lumbago and leg pain caused by lumbar tuberculosis, lumbar tumor, lumbar canal stenosis, or complete disc herniation and prolapse; (2) patients with bleeding tendency, gastrointestinal bleeding or other chronic hemorrhagic diseases within the past month; (3) women who are pregnant or breast-feeding; (4) allergic constitution or known components of the drug; (5) patients with serious diseases of heart, lung, liver, kidney, hematopoietic system, immune system, etc.

Design outcomes

Primary

Measure	Time frame
VAS score;	—

Secondary

Measure	Time frame
Oswestry dysfunction index questionnaire;JOA score;Related signs and symptoms;Quality of Life;	—

Countries

China

Contacts

Public ContactHe Yanlin

Hinye Pharmaceutical Co., Ltd

767567825@qq.com+86 15084974669

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026